Archives
DiscoveryProbe FDA-approved Drug Library: Mechanistic Screen
2026-09-02
The DiscoveryProbe FDA-approved Drug Library can do more than support compound triage: it can anchor a mechanistic screening strategy for immune-checkpoint biology. This article shows how to connect library design, TR-FRET screening, cellular validation, and orthogonal pharmacology using the ICOS/ICOSL study as a practical model.
Morin, AMPD2, and Podocyte Energy Failure
2026-09-02
A 2025 study identifies excessive adenosine 5′-monophosphate deaminase activity, particularly AMPD2, as a mechanistic link between fructose exposure, mitochondrial energy disruption, and podocyte injury. Using podocyte cultures and high-fructose-fed rats, the authors show that Morin reduces metabolic and structural abnormalities, supporting AMPD2 as a candidate target in fructose-associated glomerular damage.
Prostaglandin E2 Workflows for Immune Signaling
2026-09-01
Prostaglandin E2 enables controlled interrogation of EP-receptor signaling across inflammation research, immune regulation, and tissue models. This guide combines receptor-aware dosing, practical handling, reference-study context, and troubleshooting for more reproducible PGE2 experiments.
Carbapenemase Transmission in CREC Across Guangdong
2026-09-01
A 2025 BMC Microbiology study integrated gene localization, conjugation testing, antimicrobial susceptibility testing, mobile-element analysis, and strain typing to characterize carbapenem-resistant Enterobacter cloacae from eight Guangdong teaching hospitals. Its central finding is that plasmid-associated blaNDM-1 was common and highly transferable, linking multidrug resistance with both horizontal dissemination potential and hospital-spanning strain relatedness.
PERK Loss Sensitizes Colorectal Cancer to Ferroptosis
2026-08-31
The reference study identifies PERK as a negative regulator of ferroptosis in colorectal cancer, linking endoplasmic reticulum stress signaling to SLC7A11-mediated redox control. Its combination of cell-based perturbation, promoter analysis, tumor models, and patient-data validation provides a mechanistic framework for testing PERK loss as a strategy to expose apoptosis-resistant tumors to ferroptotic death.
Polybrene for Viral Transduction and p53 Models
2026-08-31
Polybrene (Hexadimethrine Bromide) improves viral delivery and can help researchers build consistent mutant-p53 cell models without being mistaken for a p53-activating drug. This guide connects practical transduction workflows with assay design, cytotoxicity controls, and troubleshooting for lentiviral, retroviral, and lipid-mediated DNA delivery.
DAPI Nuclear Stain Solution: Practical Guide
2026-08-30
DAPI (4',6-Diamidino-2-Phenylindole) Nuclear Stain Solution provides a pre-diluted fluorescent DNA binding dye for nuclear visualization, endpoint cell viability assessment, and apoptosis-related morphology studies. It is intended mainly for fixed or membrane-compromised samples analyzed by fluorescence microscopy or flow cytometry, rather than routine live-cell imaging.
Tianhuang Formula, RAGE/POMC, and Metabolic Control
2026-08-29
A 2026 pre-proof study identifies RAGE as a central nervous system target of berberine within Tianhuang Formula and links RAGE/POMC signaling to hypothalamic neuronal apoptosis, autophagy, and glucolipid regulation. Its integrated computational, cellular, and animal design offers a mechanistic framework for metabolic disease research, while causal validation and translation beyond metabolism remain open questions.
Plk1 Control of p31comet in Mitotic Checkpoint Exit
2026-08-28
The reference study identifies Polo-like kinase 1 (Plk1) as a negative regulator of p31comet-mediated mitotic checkpoint complex disassembly. By combining HeLa cell extracts, purified proteins, phosphorylation analysis, and an S102A mutant, the authors show how Plk1 phosphorylation of p31comet restrains TRIP13-dependent checkpoint silencing during active mitosis.
ATG9A, PTOV1, and 14-3-3 Cancer Mechanisms
2026-08-28
The reference study identifies ATG9A and PTOV1 as previously uncharacterized 14-3-3-interacting proteins and defines distinct regulatory mechanisms linking them to basal autophagy and oncogenic signaling. Its combination of proximity labeling, quantitative proteomics, biochemical validation, and perturbation experiments provides mechanistic hypotheses for autophagy control and PTOV1 stability, while also highlighting limits for direct therapeutic translation.
Leupeptin Hemisulfate: Reliable Assay Control
2026-08-27
Learn how Leupeptin, Microbial (Leupeptin hemisulfate), SKU A2570, can help control proteolysis and interpret cell viability, proliferation, cytotoxicity, autophagy, and antiviral experiments. This scenario-based guide emphasizes potency context, fresh-solution handling, membrane-permeability limits, and practical vendor-selection criteria.
Alda 1: Designing Better ALDH2 Cardiac Assays
2026-08-27
Alda 1 is an ALDH2 activator that enables genotype-aware studies of aldehyde detoxification, cardiac stress, and cardiomyocyte proliferation. This guide translates recent pressure-overload findings into practical assay decisions while distinguishing biochemical activation from downstream cardioprotection.
nor-NOHA Acetate: Arginase Inhibition Guide
2026-08-26
nor-NOHA acetate is a reversible arginase inhibitor for research on arginine metabolism, HepG2 biology, vascular signaling, and immunometabolism. Its strongest product-linked evidence includes a reported 0.5 μM Ki against rat liver arginase, while cancer and vascular findings remain model-specific rather than clinical evidence.
Bacitracin B1670: Protocol and QC Guide
2026-08-26
Bacitracin (SKU B1670) is a peptide antibiotic for controlled antibacterial research involving bacterial cell wall and peptidoglycan synthesis. This guide covers preparation, controls, storage, and interpretation boundaries; the product is for scientific research only and should not be used for diagnostic, clinical, or medical purposes.
EZ Cap™ OVA mRNA: Immune Research Workflow
2026-08-25
EZ Cap™ OVA mRNA provides a defined, Cap 1–modified Ovalbumin mRNA input for antigen-expression assays, immune response immunogen studies, and delivery-platform comparisons. Its standardized sequence, poly(A) tail, and compatibility with low-inflammation lipid nanoparticle research help separate delivery performance from antigen variability.
814 records 9/55 page Previous Next First page 上5页 678910 下5页 Last page